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Abstract
Fuchs’ endothelial corneal dystrophy (FECD) is the most common repeat expansion disorder. FECD impacts 4% of U.S.
population and is the leading indication for corneal transplantation. Most cases are caused by an expanded intronic CUG
tract in the TCF4 gene that forms nuclear foci, sequesters splicing factors and impairs splicing. We investigated the sense and
antisense RNA landscape at the FECD gene and find that the sense-expanded repeat transcript is the predominant species in
patient corneas. In patient tissue, sense foci number were negatively correlated with age and showed no correlation with sex.
Each endothelial cell has 2 sense foci and each foci is single RNA molecule. We designed antisense oligonucleotides (ASOs)
to target the mutant-repetitive RNA and demonstrated potent inhibition of foci in patient-derived cells. Ex vivo treatment of
FECD human corneas effectively inhibits foci and reverses pathological changes in splicing. FECD has the potential to be a
model for treating many trinucleotide repeat diseases and targeting the TCF4 expansion with ASOs represents a promising
therapeutic strategy to prevent and treat FECD.
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Introduction
Corneal disorders impacting corneal clarity are a leading cause
of vision loss and blindness globally. Fuchs’ endothelial corneal
dystrophy (FECD, MIM 136800) is an age-related degenerative
disorder of the endothelium that affects 4% of individuals over
the age of 40 in the United States and is the leading indication
for corneal transplantation (1,2). The corneal endothelium is the
inner hexagonal monolayer responsible for maintenance of
stromal dehydration and corneal clarity. In FECD, the post-
mitotic endothelium undergoes premature senescence and
apoptosis (3–9). Descemet’s membrane, the basement mem-
brane of the endothelium, becomes markedly thickened and
develops focal excrescences called guttae. These guttae are
diagnostic of FECD and are detected by clinical slit-lamp biomi-
croscopy (10). Confluent central guttae and concomitant loss of
endothelial cell density results in corneal edema, scarring and
loss of vision.
Recently, the potential for treating FECD has been trans-
formed by the discovery that expansions at the intronic CTG
triplet repeat polymorphism of TCF4 (MIM 602272) account for
70% of FECD cases in the United States (11–14). TCF4 expansions
of greater than 40 CTG repeats confer significant risk for devel-
oping FECD (12). Expanded CUG-repeat RNA transcripts (CUGexp)
accumulate as nuclear foci in FECD endothelial tissue that can
be visualized by fluorescent in-situ hybridization (FISH) (15). The
splicing factor muscleblind-like 1 (MBNL1) co-localizes with
CUGexp nuclear foci and its sequestration and functional deple-
tion correlate with mis-splicing of MBNL1-sensitive exons (16).
Myotonic dystrophy type 1 (MIM 160900) patients with CTG
expansions within the 30-untranslated region of DMPK (MIM
605377) are also at increased risk for FECD and form CUGexp-
MBNL1 foci in corneal endothelium (17).
Currently, the only effective therapy for FECD is corneal
transplantation. Surgical outcomes including visual acuity have
improved markedly over the last decade as endothelial kerato-
plasty (EK) techniques have overtaken penetrating keratoplasty
for FECD (18). However, modern EK techniques are still associ-
ated with significant complications including a 28.8% detach-
ment rate of allograft and 1.7% primary graft failure rate in the
immediate post-operative period necessitating additional surgi-
cal interventions (19). Reported EK graft failure rates for FECD
are 3.8–5% at 5 years in specialized, single-center studies (20,21).
Even when the initial surgery is successful, nearly a quarter of
patients develop glaucoma after EK that require further medical
or surgical treatments (21). Access to tertiary-care corneal trans-
plant surgeons and a suitable corneal donor pool with eye bank-
ing support to process tissue limits EK as a treatment option
globally.
As a rule, visual disability must be substantial before surgery
becomes an acceptable option to patients and many patients
suffer loss in quality of vision for years prior to seeking surgical
treatment. A less or non-invasive medical treatment option
would benefit hundreds of thousands of individuals with early
or moderate stage FECD by halting disease pathogenesis.
Over 20 diseases are caused by expansions of nucleotide
repeats within genes (22). These expanded repeats can occur
within coding regions, introns, or 30-untranslated regions and
the pathogenic mechanisms linking the molecular mutation to
disease are diverse. For Huntington’s disease, the disease
appears to be caused by the mutant protein, while for
Friedreich’s ataxia the disease appears to be caused by repres-
sion of wild-type protein expression. Understanding mecha-
nism and the molecular vulnerabilities of the mutant RNA is
critical to the design of gene specific drugs capable of treating
disease.
FECD has the potential to be a model for studying the patho-
genesis and treatment of diseases caused by expanded repeats.
Unlike most other repeat diseases, where affected tissue is usu-
ally inaccessible and can be examined only by autopsy, the cor-
neal endothelium is only a half-millimeter from the surface of
the eye. Both disease progression and treatment outcomes can
be followed by simple non-invasive measurements. For preclin-
ical studies such as the one presented here, the ready availabil-
ity of patient corneal tissue provides an ex vivo model for
evaluating molecular pathology and drug action. Some lessons
learned from FECD may be broadly applicable to other diseases
that affect less accessible locations.
In this report, we qualitatively and quantitatively character-
ize RNA transcription at the FECD locus as a target for molecular
therapy. We show that antisense oligonucleotides (ASOs) can
block RNA foci in patient-derived cells. ASOs can enter corneal
tissue and correct splicing changes in ex vivo human corneas
with FECD. Targeting the TCF4 expansion with oligonucleotides
is a promising therapeutic strategy to prevent or treat FECD, the
most common human repeat expansion disorder.
Results
Sense and antisense transcription at the TCF4 locus
Because the CTG repeat expansion is outside the protein-
encoding region of the TCF4 gene, defining the landscape of
RNA synthesis is essential for understanding the molecular
basis of FECD. The disease-associated expanded CUG repeat
occurs within intron 2 of TCF4 pre-mRNA (Fig. 1A) (23). Many
genes, including some with expanded repeats, express tran-
scripts that are in an antisense orientation relative to mRNA
and these antisense transcripts have the potential to contribute
to disease (24,25). We used quantitative strand-specific PCR
(qPCR) to evaluate antisense transcription at the TCF4 locus and
detected an antisense transcript containing the expanded CAG
repeat in the F35T (1500 CUG repeats) cell line derived from a
patient with FECD (Fig. 1B; Supplementary Material, Fig. S1).
We used FISH to examine the presence of sense or antisense
transcript foci within two different corneal endothelial cell lines
derived from patients with FECD. For both F35T (1500 CUG
repeats) and F45 (71 CUG repeats) cell lines, sense foci were
detected (Fig. 1C). No obvious antisense foci were detected. We
also used FISH to examine foci in corneal endothelial tissue
from a FECD patient with the TCF4 repeat expansion and
observed both sense and antisense foci (Fig. 1D). No foci were
detected in endothelial cells of control donor cornea endothelial
tissue lacking the expansion.
Analysis of sense and antisense foci in patient tissue
After establishing that both sense and antisense foci were
detectable in FECD corneal endothelial tissue, we initiated a
quantitative analysis of corneal surgery samples from 20 differ-
ent FECD patients to assess the correlation of RNA expression
with disease, age, expanded allele length and sex. Tissue sam-
ples were used for FISH to evaluate the percentage of endothe-
lial cells with at least one detectable focus and the number of
foci per 100 cells.
Both sense and antisense foci were detected in all 20 FECD
tissues with the TCF4 triplet repeat expansion (Table 1).
Sense foci were found in 62–95% of cells while the antisense foci
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were found in only 3–27% of the cells. Foci are not numerous,
with 1–2.7 sense foci and .07–0.6 antisense foci per cell. No foci
were observed in a healthy control tissue or a FECD tissue
without expansion. Genetic heterogeneity of FECD (17) would
account for the lack of foci in endothelial tissue explants from
patients without repeat expansions resulting in the same
phenotype.
We observed a significant negative correlation between age
and both the percentage of cells with sense foci (P ¼ 0:006Þ and
the number of sense foci per cell (P ¼ 0:016Þ (Fig. 2A). Tissues
were harvested from patients with late stage disease and the
correlation of decreased foci with age may be due to earlier dis-
appearance of cells with relatively large numbers of foci. There
was a trend towards a positive correlation between the number
of sense foci and the length of the triplet repeat allele, but it did
not reach the statistical significance (Fig. 2B). Although women
are two to four times more likely to be affected by FECD (26,27),
there was no significant correlation between sex of subjects and
sense foci number (Fig. 2C). There was no significant correlation
between foci number for the antisense transcript and age or sex
(Supplementary Material, Fig. S2).
Copy number of mutant RNAmolecules in patient cells
Defining the number of disease-causing molecules is funda-
mental to understanding of FECD pathology and successful
drug development. Using qPCR (28), we measured a copy num-
ber of less than 3 TCF4 intronic transcripts per cell in patient tis-
sue samples, control tissue, as well as in F35T cells (Fig. 3;
Supplementary Material, Figs S3 and S4). The patient-derived
cells used in this study were heterozygous for mutant TCF4 and
our qPCR methods detect both the mutant and wild-type TCF4
intron 2 transcripts. Therefore, the number of mutant tran-
scripts is a fraction of the total measured RNA molecules.
Using FISH, we determined that most cells have only one or
two sense foci (Fig. 3A and B; Table 1). Thus, there is an approxi-
mately a one-to-one correspondence between mutant intronic
RNA transcripts per cell and sense foci per cell, suggesting each
focus is a single mutant TCF4 RNA molecule. Our laboratory
recently reported that c9orf72 disease-related foci are also each
composed of one mutant expanded repeat RNA (28). Similarly,
Wansink and colleagues have reported that the mutant RNA
expanded CUG transcript associated with myotonic dystrophy
Figure 1. Sense and antisense RNA foci are detected in FECD corneal endothelial cells by fluorescent microscopy. (A, B) Scheme showing TCF4 pre-mRNA and antisense
transcripts with the location of the expanded CUG and CAG repeat regions. (C) FISH images of CUGexp RNA foci in two patient-derived FECD endothelial cell lines (F35T,
F45) compared with a healthy control endothelial cell line (Zante). A (CAG)6CA RNA probe was used for detecting the sense CUG
exp foci. (D) Representative images of
sense CUGexp or antisense CAGexp RNA foci in one FECD patient corneal tissue compared with a healthy control endothelial tissue. A (CUG)6CU RNA probe was used for
detecting the antisense CAGexp foci.
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is also low abundance (29). These data cumulatively suggest
that small numbers of RNA molecules have a big impact on
repeat expansion disease pathogenesis making them ideal ther-
apeutic targets.
Antisense oligonucleotides inhibit foci in vitro
ASOs have several advantages as starting points for FECD drug
discovery. ASOs are synthetic nucleic acids that can recognize
complementary RNA sequences inside cells and sequence-
specifically modulate gene expression in vivo (30). Several ASOs
have shown encouraging results in late stage clinical trials,
including two recent FDA approvals to alleviate spinal muscular
atrophy (31) and muscular dystrophy (32).
We chose to test the ability of anti-CUG ASOs to block foci
and serve as a starting point for therapeutic development. ASOs
targeting the DMPK CUG repeat RNA can reverse cellular pheno-
types of myotonic dystrophy (33). Our laboratory and others
have shown that synthetic nucleic acids can target expanded
CAG repeats within genes causing Huntington’s disease,
Machado Joseph Disease and dentatorubral-pallidoluysian atro-
phy (34–36).
FECD sense foci are much more prevalent than antisense foci,
making the expanded repeat within the sense transcript the logi-
cal target of a molecular therapy. We synthesized locked nucleic
acid (LNA) ASOs complementary to the CUG repeat in all three
registers relative to the target sequence (Table 2). LNA substitu-
tions were spread through the ASO, creating designs that would
not be expected to recruit RNase H to cause degradation of target
RNA. LNA is an advantageous chemical modification for drug
development because it contains a conformationally restricted
ribose that enables high-affinity binding to cellular RNA targets
(37,38).
All three 19-mers (LNA 1–3) were potent inhibitors of CUG
foci in F35T or F45 endothelial cell lines (Fig. 4A and B). The 16-
mer LNA 4 is less effective. LNAs 1, 2 and 3 had higher affinities
for complementary targets, as measured by melting tempera-
ture, than LNA 4 (Table 2), probably explaining their greater effi-
cacy. We were unable to assess the impact of the ASO-LNAs
complementary to the sense strand on the antisense foci
because the lack of any detectable antisense foci in the FECD
cell lines utilized in this study. We also tested a 21-mer ASO
that was entirely substituted with 20O-methyl RNA and found
that it was less effective (Supplementary Material, Fig. S5).
Transfection of LNAs did not reduce levels of TCF4 RNA
(Supplementary Material, Fig. S6).
Free ex vivo uptake and activity of ASOs in FECD
human corneas
To evaluate whether delivery to corneal tissue was feasible, we
first tested ‘gymnotic’ or ‘naked’ (transfection reagent free)
uptake (39) of a fluorophore-labeled oligonucleotide into the
endothelium of ex vivo human corneas (Supplementary
Material, Fig. S7). Uptake of ASO was observed within both the
cytoplasm and nuclei.
After establishing that ex vivo uptake was possible, we were
fortunate to be able to extend our investigation by accessing
human corneas deemed unsuitable for transplantation because
of findings of FECD and subsequent confirmation of the muta-
tion by genotyping. We treated the corneas of human FECD-
patient donors using a non-complementary control (LNA LC) or
Table 1. Summary table of patient corneal endothelial tissue samples
ID Age Sex Ethnicity CTG
repeat
% of total cells
with sense foci
Number of sense
foci per 100 cells
% of total cells
with antisense foci
Number of antisense
foci per 100 cells
Control
2014-1670 45 M Black 23, 35 0.0 0.0 0.0 0.0
CA052 75 F White 12, 17 0.0 0.0 0.0 0.0
FECD
CA056 59 F White 24, 150 92.0 211 6.0 7.2
VVM573 50 F White 12, 130 91.2 217 7.7 9.0
VVM672 55 F White 20, 130 93.0 171 2.8 5.0
CA105 58 M White 12, 130 82.8 195 7.1 8.0
CA120 58 F White 16, 130 84.9 168 5.8 7.0
AK009 61 F White 18, 130 79.7 171 8.3 13.0
CA033 62 M White 71, 130 95.0 277 10.0 12.0
CA063 64 F White 12, 74 92.3 210 6.2 7.0
CA045 66 F White 15, 120 91.7 210 8.0 9.0
CA026 67 M White 12, 67 85.0 160 5.0 6.0
CA047 67 M White 12, 91 69.0 129 41.0 62.0
CA054 68 M White 12, 79 90.0 272 6.0 6.7
VVM513 70 M White 12, 88 93.7 212 6.1 7.0
CA062 71 M White 17, 87 89.0 173 17.0 20.0
CA027 71 F White 12, 74 86.3 143 27.0 13.0
CA050 73 F White 17, 74 90.0 191 13.0 16.0
CA048 74 F White 12, 54 62.0 127 12.6 20.0
CA049 75 F White 17, 1000 81.0 144 15.0 17.0
CA053 78 F White 14, 84 70.0 134 4.0 4.0
VVM289 86 F White 12, 87 61.9 96 3.8 4.0
Sample 2014-1670 is a healthy control. CA052 is a FECD tissue without CTG expansion (negative control). Twenty FECD samples are with CTG expansions. Sense foci
were found in 84.0% of cells [standard deviation (SD)¼10.4] compared to the antisense foci found in 10.6% of the cells (SD¼9.1) (P ¼ 2:1 1024). Foci are not numerous,
with 1.8 sense foci (SD¼4.7) and 0.13 antisense foci per cell (SD¼0.13) (P ¼ 2:9 1013). n¼300–500 cells evaluated per patient sample.
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ASO LNA 1 (Fig. 5A; Supplementary Material, Fig. S8). After
dissection, the Descemet’s membrane with endothelium was
analyzed by FISH. We found that LNA 1, but not the non-
complementary LNA LC, blocked foci formation (Fig. 5B and C).
The expanded repeat within TCF4 has been shown to affect
splicing of MBNL1-sensitive exons in FECD corneal tissue (16).
Binding of the LNAs would block the mutant repeat, preventing
the RNA from interacting with MBNL1 or other factors that
influence splicing. To determine whether LNA 1 was affecting a
cellular phenotype, we examined splicing of INF2, MBNL1 and
ADD3, all genes previously identified as being influenced by
mutant TCF4. We observed alteration of splicing in all three
genes upon administration of LNA 1, partially restoring alterna-
tive splicing to that observed in normal corneal tissues
(Fig. 5D and E).
Discussion
ASOs as treatment for FECD
FECD is a leading cause of vision loss and by far the most com-
mon disease caused by mutant expanded trinucleotide repeats.
We introduce ASOs as a potential molecular therapy to correct a
genetic disorder in human corneas. ASOs targeting the mutant
TCF4 repeat effectively reduced CUGexp foci formation and
pathologic splicing in ex vivo human FECD corneas.
Figure 2. Effect of age, repeat length, and sex on foci. (A) Graphs show significant
negative correlation between % of cells with sense RNA foci or number of sense
foci per 100 cells with age of subject. (B) There is a trend toward a positive corre-
lation between sense foci and triplet repeat allele length. (C) Graphs show no
correlation between sense foci and patient gender.
Figure 3. One-to-one correspondence between sense foci and mutant TCF4 RNA
molecules in FECD. (A) Analysis of sense foci in F35T cells. (B) Sense foci distri-
bution in F35T cell line. Majority of F35T cells have one or two sense foci in
nuclei. (C) Copy number of GAPDH, TCF4 intron 2, TCF4 exon 2/3, TCF4 exon 18
transcripts measured with qPCR in F35T cells. F35T cells have less than three
TCF4 intron 2 molecules. (D) Copy number of TCF4 transcripts in healthy control
corneal endothelial tissues (n ¼ 3). (E) Copy number of TCF4 transcripts in FECD
corneal endothelial tissues (n ¼ 3). TCF4 intron 2 molecules are rare RNA species
in endothelial tissue. One-to-one correspondence between intronic RNA tran-
scripts per cell and sense foci per cell suggests that each focus is a single mutant
TCF4 RNA molecule.
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Our laboratory and others have reported that a greater than
30-fold increased risk for FECD is correlated with an expanded
CUG repeat within the TCF4 gene (11–13). There are at least
three possible explanations linking the mutation to disease:
1). The expansion with the chromosomal DNA affects gene
expression directly, either at the TCF4 locus or at nearby genes;
2). the expansion within the RNA affects gene expression or
gene splicing or 3). the expansion within the RNA acts as a tem-
plate for synthesis of RAN peptides, a phenomenon that has
been noted for other expanded repeat disease genes (40).
Our study was not intended to definitively distinguish
between these options but does provide some insights into
potential roles for mutant RNA. There are an average of 1–2 foci
or mutant RNA molecules per cell suggesting that, if the mutant
RNA is involved directly, small numbers of RNA molecules must
have an outsized impact on disease.
Evidence suggesting that these small numbers can impact
disease includes our previous report that FECD is observed in
myotonic dystrophy (DM1) patients that have a CUG expansion
within the DMPK gene (17). DM1 cells are also characterized by
1–2 foci per cell (29) and the association of FECD with CUG
expanded repeats in two different genes implicates the mutant
RNA as causative rather than the host gene. The repeat DM1
CUG RNA transcripts within the DMPK gene have been demon-
strated to serve as templates for repeat-associated non-ATG
(RAN) translation resulting in toxic peptides (40). We did not
examine the expression of RAN peptides in this study and such
experiments are warranted to understand how repeat CUG RNA
transcripts result in dysfunction of the corneal endothelium.
In DM1, experimental evidence suggests that the mutant
expanded repeat CUG RNA transcripts sequester the splicing
factor MBNL1 and contribute to cellular dysfunction by trigger-
ing mis-splicing (41) and splice defects have previously been
noted in FECD pathogenesis (16). We provide experimental data
suggesting that ASOs targeting the sense RNA transcript
reverses foci formation and pathologic splicing. The ability of
ASOs to target the mutant expanded RNA and at least partially
correct a splicing defect is further evidence supporting the
hypothesis that small numbers of mutant RNA can contribute
to disease.
ASOs are experiencing a wave of success in the clinic and
the eye may be a particularly advantageous organ for targeting
with synthetic oligonucleotides. Vitravene, the first ASO drug
approved by the FDA, was administered by intraocular (intravi-
treal) injection for cytomegalovirus retinitis (42). Intracameral
injection would place an ASO into the anterior chamber of the
eye in direct contact with the corneal endothelium. The small
volume of the eye will greatly reduce the cost of treatment rela-
tive to systemic administration. Other trials with ASOs have
shown long duration of effects (31), suggesting that infrequent
Table 2. List of CUG repeat-targeting LNA-ASOs
Name Sequence 50-30 Mass (observed/
calculated)
Tm (C)
LNA 1 CAGCAGCAGCAGCAGCAGC 6273.56/6273.05 78.1
LNA 2 AGCAGCAGCAGCAGCAGCA 6325.52/6325.08 77.4
LNA 3 GCAGCAGCAGCAGCAGCAG 6313.56/6313.07 77.9
LNA 4 AGCAGCAGCAGCAGCA 5317.50/5317.27 74.1
LNA base: bold; DNA base: normal caps; all oligomers are fully phosphorothioate backbones. Tm was detected by equal amount (1 mM each) of LNAs with complemen-
tary DNAs.
Figure 4. LNA-ASOs inhibit CUGexp foci in F35T (CUG 22/1500) and F45 (CUG 16/71) endothelial cell lines. (A) Effect of LNAs on inhibition of CUGexp RNA foci in F35T cells.
CM: non-complementary negative control duplex RNA; LC: LNA analog of CM. (B) Effect of LNAs on inhibition of CUGexp foci in F45 cells. Error bars represent SEM.
*P < 0.05; ** P < 0.01; *** P < 0.001 compared with control LC. At least one hundred cells were analyzed for each experiment.
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Figure 5. An LNA-ASO reduces CUGexp foci and reverses mis-splicing in ex vivo human FECD corneas. (A) Scheme outlining the experiment in ex vivo human corneas.
Pairs of corneas from FECD-patient donors and control donors were obtained from eye bank and were treated with ASOs. Corneas from right eyes were used to assess
CUGexp foci. Corneas from corresponding left eyes were used to assess splicing events. (FECD Tissue 1 from 54-year-old FECD-patient donor, 17/110 CTG repeat; FECD
Tissue 2 from 51-year-old FECD-patient donor, 13/130 CTG repeat). (B) FISH images of FECD corneal endothelial tissue 1 treated with control LNA-LC and LNA 1.
(C) Effect of LNA 1 on inhibition of CUGexp foci in two FECD corneas. About 200 cells or more were analyzed for each treatment. (D) RT-PCR gel images showing effect of
LNA 1 on the splicing of INF2, MBNL1 and ADD3 in FECD corneal endothelial tissues. Flanking RT-PCR primers were used to assess exon inclusion or exon exclusion.
(E) Averaged quantitative bar graphs of splicing events shown in (D). ImageJ was used to compare density of bands on gel. Error bars represent SEM.
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dosing may be possible, further lowering cost and increasing
patient convenience.
The affected tissue in FECD is only a half-millimeter from
the surface of the eye and topical administration by eye drops
may be possible. Topical administration of ASO eye drops have
already been found to be effective, safe and well tolerated in
phase II FDA trials of aganirsen for viral keratitis-induced cor-
neal neovascularization (43). Because systemic administration
is unnecessary, the likelihood of systemic off-target effects that
might cause toxicity is low.
Early detection of FECD in patients with the TCF4 trinucleo-
tide repeat expansion is possible by genetic testing and routine
examination of the cornea. In parallel with further testing of
compounds that modulate mutant repeat RNA, it will be essen-
tial to rigorously explore the molecular natural history of FECD
to guide clinical trials. Our group has documented incomplete
penetrance of the FECD trait in the setting of the triplet repeat
expansion in the TCF4 gene (12). Additional studies are neces-
sary to develop a FECD risk propensity scoring system based on
parameters such as TCF4 triplet repeat allele length, sex, age,
ethnicity, family history and corneal examination findings to
identify individuals who would benefit from preventative
molecular therapies (14).
Any drug treatments for FECD would likely need to start
early in the disease process and continue for an extended
period. Identification of biomarkers will provide critical guides
for convenient and timely monitoring of disease progression so
that the length of clinical trials can be minimized. Treatments
will therefore need to be minimally invasive and convenient for
patients. A safe, non-toxic and convenient preventative therapy
may be indicated even in subjects where physical manifestation
of early stage FECD is not yet apparent but would certainly be
warranted after early stage disease is detected but before signif-
icant loss of vision occurs.
Conclusions
Our data provides a rationale of the use of ASOs targeting the
small number of mutant TCF4 repeat RNA molecules within
cells as a therapeutic strategy to prevent and treat vision loss
caused by FECD. Reversal of the molecular phenotype in an ex
vivo human FECD cornea model may serve as relevant
pre-clinical development data to justify use of a lead ASO thera-
peutic compound in human trials once dosing and delivery pro-
tocols are optimized in animal and ex vivo human corneal
models (44,45). An oligonucleotide treatment for FECD would
advance clinical practice by realizing the promise of precision
medicine for a common human disease. Beyond FECD, the abil-
ity to introduce oligonucleotides into corneal tissue suggests
the potential to control gene expression associated with many
other disorders, such as the group of TGFBI-associated corneal
dystrophies and broaden the options for using ASOs in the eye.
Materials and Methods
Subjects
Subjects underwent a complete eye examination including slit
lamp biomicroscopy by a cornea fellowship-trained ophthal-
mologist. Subjects underwent EK for FECD severity Krachmer
grade 5 (5 mm central confluent guttae without stromal
edema) or 6 (5 mm central confluent guttae with stromal
edema) assessed by slit lamp microscopy (46). Surgically
explanted endothelium-Descemet’s membrane monolayers
were fixed in a 4% phosphate-buffered formaldehyde, equili-
brated in a 30% sucrose solution for cytoprotection, and frozen
in Tissue-Tek Optimal Cutting Tissue (OCT) compound (Sakura,
Torrance, CA) for FISH studies (15). Genomic DNA was extracted
from peripheral blood leukocytes of each study subject using
Autogen Flexigene (Qiagen, Valencia, CA).
Corneal endothelial samples from post-mortem donor cor-
neas preserved in Optisol GS corneal storage media (Bausch &
Lomb, Rochester, NY) were obtained from the eye bank of
Transplant Services at UT Southwestern. Certified eye bank
technicians screened the donor corneal endothelium with slit
lamp biomicroscopy and Cellchek EB-10 specular microscopy
(Konan Medical). Donor corneal tissue with FECD was identified
by the presence of confluent central guttae. Endothelium-
Descemet’s membrane monolayers from donor corneas were
micro-dissected and stored as previously described (15). DNA
from the remaining corneal tissue of each sample was extracted
with TRIzol reagent (ThermoScientific).
TCF4 CTG18.1 polymorphism genotyping
Genomic DNA from subjects’ peripheral leukocytes or corneal
tissue was used for genotyping. The CTG18.1 trinucleotide
repeat polymorphism in the TCF4 gene was genotyped using a
combination of short tandem repeat (STR) and triplet repeat
primed polymerase chain reaction (TP-PCR) assays as we have
previously described (12). For the STR assay, a pair of primers
flanking the CTG18.1 locus was utilized for PCR amplification
with one primer labeled with FAM on 50 end. The TP-PCR assay
was performed using the 50 FAM-labeled primer specific for the
repeat locus paired with repeat sequence targeted primers for
PCR amplification. PCR amplicons were loaded on an ABI
3730XL DNA analyzer (Applied Biosystems, Foster City, CA) and
the results analyzed with ABI GeneMapper 4.0 (Applied
Biosystems). Large triplet repeat expansions were sized by
southern blot analysis using digoxigenin-labeled probes (14).
Detection of TCF4 repeat transcript
TCF4 expression was analyzed by qPCR on a 7500 real-time PCR
system (Applied Biosystems) using iTaq SYBR Green Supermix
(Bio-rad). Data was normalized relative to levels of HPRT1
mRNA. Primers specific for TCF4 exon18 are as follows: F 50-TG
ACGATGAGGACCTGACAC-30; R 50-GTCTGGGGCTTGTCACTCTT-
30. Primers for TCF4 intron2: F 50-GAGAGAGGGAGTGAAAGAGAG
A-30; R 50-GGCAATGTCCATTTCCATCT-30.
To detect antisense transcript, cDNA was generated from
0.25 lg of total RNA using the SuperScript III system (Invitrogen)
with strand-specific reverse primers attaching a linker sequence
LK. Next, cDNA was amplified by PCR with strand-specific for-
ward and LK primers (Supplementary Material, Fig. S1). The PCR
products were cloned and Sanger sequenced to verify their
specificity.
Human corneal endothelial cell culture
The ‘Zante’ human corneal endothelial cell line derived from a
healthy control subject expressing TCF4 transcript with approxi-
mately 16–19 CUG repeats was a generous gift of Dr Danielle
Robertson (UT Southwestern) (47). The F35T corneal endothelial
cell line derived from FECD patient expressing TCF4 transcript
with approximately 1500 CUG repeats was a generous gift of Dr
Albert Jun (Johns Hopkins). The F45 corneal endothelial cell line
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was a primary culture from a donor cornea from FECD patient
expressing TCF4 transcript with approximately 71 CUG repeats.
The dissected Descemet’s membrane monolayer was incubated
with 2 mg/ml collagenase A (Roche) in culture media at 37C for
4 h to dissociate the cells, spun down at 800 g for 5 min, and
plated on culture dish pre-coated with fibronectin (FNC)
(Athena Environmental Sciences). Cells were grown in modified
Eagle’s minimal essential media (OptiMEM) (ThermoFisher) sup-
plemented with 8% fetal bovine serum, 5 ng/mL human
epidermal growth factor (ThermoFisher), 20 ng/mL nerve
growth factor (Fisher Scientific), 100 mg/mL bovine pituitary
extract (ThermoFisher), 20 mg/mL ascorbic acid (Sigma-Aldrich),
200 mg/L calcium chloride (Sigma-Aldrich), 0.08% chondroitin
sulfate (Sigma-Aldrich), 50 mg/mL gentamicin (ThermoFisher)
and antibiotic/antimycotic solution (diluted 1/100) (Sigma-
Aldrich) (48). Cultures were incubated at 37C in 5% CO2 and
passed when confluent.
Transcript copy number measurement by qPCR
Transcript copy number measurement was performed as we
described previously (28). Briefly, standard RNA was made by
in vitro transcription with corresponding purified PCR fragment
containing SP6 promoter sequence. After checking RNA with
Bioanalyzer (Agilent), a serial dilution of purified standard RNA
ranging from 10 to 105 copies was used to construct standard
curve for qPCR efficiency following reverse transcription. The
qPCR was performed on a CFX Connect Real-Time System (Bio-
Rad). Ct values in each dilution were measured in triplicate. To
determine transcript copy number per cell, total RNA was
extracted by TRIzol (ThermoScientific) for F35T cell line or by
NucleoSpin RNA XS kit (Fisher Scientific) for endothelial tissue
samples and used to do reverse transcription. Cell number of
F35T was counted by two methods: hemocytometer and Z1
Particle Counter (Beckman Coulter). Cell number of control
endothelial tissue was calculated as p  (d/2)2  cell density (d is
the diameter of trephine used for dissection; endothelial cell
density measured by specular microscopy was provided by eye
bank). Endothelial cell density of FECD tissue was estimated as
500 cells/mm2. For each transcript, a serial dilution of cDNA was
used. Ct values in each dilution were measured in triplicate.
Copy number per cell was calculated by using the standard
curve for qPCR efficiency of each transcript. For cells, data were
analyzed from two batches of F35T cells. For tissues, data were
analyzed from three control tissues and three FECD tissues.
Results are showed as the mean6SD. Primers used to make
PCR product are: GAPDH E1F1 SP6 (50-ATTTAGGTGACACTAT
AGAACTCTGCTCCTCCTGTTCGAC-30), GAPDH E5R1 (50-TTGAT
TTTGGAGGGATCTCG-30), TCF4 E2F1 SP6 (50-ATTTAGGTGACACT
ATAGAATGCTAAAATGCATCACCAACA-30), TCF4 E3R1 (50-GAGC
CAGTAAAATGTCCACTTG-30), TCF4 intron2dwF1 SP6 (50-ATTTA
GGTGACACTATAGAATGTTGCACTTTCTCCATTCG-30), TCF4 intr
on2dwR1 (50-CAGGAGAGCAATTTGAAGCA-30), TCF4 E18F1 SP6
(50-ATTTAGGTGACACTATAGAATGACGATGAGGACCTGACAC-
30) and TCF4 E18R1 (50-AGGATCAGGAGCTTGGTCTG-30). Primers
and probes used for qPCR are: Human GAPD (GAPDH)
Endogenous Control (Thermo Fisher 4310884E), TCF4 E2F2 (50-TA
GGGACGGACAAAGAGCTG-30), TCF4 E3R2 (50-CCACTTGCCAAAG
AAGTTGG-30), TCF4 E2/3 probe (50-TTCACCTCCTGTGAGCAGTG-
30), TCF4 intron2dwF2 (50-TTCTCCATTCGTTCCTTTGC-30), TCF4
intron2dwR2 (50-CACTCCCTCTCTCTCCAGCA-30), TCF4 intron
2dw probe (50-GCTCTGACTCAGGGAAGGTG-30), TCF4 E18F2 (50-
ACGATGAGGACCTGACACCA-30), TCF4 E18R2 (50-GGGCTTGTCAC
TCTTGAGGT-30) and TCF4 E18 probe (50-AGAAGGCAGAGCGTGA
GAAG-30).
Synthesis and transfection of oligonucleotides
LNA phosphoramidites were synthesized from the 30-hydroxyl
precursors (Rasayan) and assembled into oligonucleotides as
described previously (49). ASOs were deprotected using concen-
trated aqueous ammonia for 16 h at 55C and were character-
ized by LCMS (Table 2). LNA ASOs were transfected into cells
with Lipofectamine RNAiMAX (Life Technologies) as described
previously (34). Cells were plated at a density of 300 000 per well
of a 6-well plate and transfected at the same time using an oli-
gonucleotide concentration of 25 nM. After 72 h, the cells were
transfected again as mentioned above and harvested 4 days
later to assess the effects for reduction of CUGexp foci using RNA
FISH/immunofluorescence.
Fluorescence in-situ hybridization
Cornea endothelial cells post oligonucleotide transfection were
harvested by trypsin and replated on glass slides. Cells were
fixed with 4% formaldehyde in 1X phosphate-buffered saline
(PBS) and permeabilized in 70% ethanol at 4C overnight. After
removing the permabilization solution, cells were washed with
buffer (10% formamide in 2X saline sodium citrate buffer [SSC])
for 5 min, and then incubated with prehybridization buffer (40%
formamide in 2XSSC) at 45C for 20 min. (CAG)6CA-50 Texas red-
labeled 2-Omethyl RNA 20-mers probe in hybridization buffer
(100 mg/mL dextran sulfate and 40% formamide in 2XSSC) was
added. The slides were placed in a humidified chamber and
incubated in the dark at 37C overnight. On the next day, cells
were washed twice with wash buffer at 37C for 15 min, and
then stained with mounting media with DAPI (H-1500; Vector
Labs).
Cells were imaged at 60 magnification using a Widefield
Deltavision microscope. Images were processed by blind decon-
volution with AutoQuant X3. Visualization of RNA foci were
made using ImageJ. For quantification, at least 20 pictures were
taken from randomly chosen microscopic fields, containing
100–300 cells for each treatment. Counting of foci was per-
formed by different investigators.
FISH of corneal endothelial tissue monolayers were per-
formed using previously described methods (15). Twenty ran-
dom archived EK samples from patients with the CTG18.1
expansion were studied. Genotyping of CTG18.1 locus was per-
formed after the time of EK using genomic DNA from subject
leukocytes. Each endothelial tissue sample was bisected with
one half used to detect sense foci using (CAG)6CA RNA probe
and other half used to detect antisense foci using (CUG)6CU RNA
probe (Integrated DNA Technologies).
Ex vivo oligonucleotide treatment of human corneas
Post-mortem human donor corneas were obtained from UT
Transplant Services. The donor corneas were incubated in
Optisol GS corneal storage media with a single stranded anti-
sense oligonucleotide LC-Cy5 (final concentration 10 lM) at 37C.
The Descemet’s membrane-endothelium monolayers were dis-
sected as reported previously (15) either after 1 day or 7 days of
treatment, stained with DAPI (Vector Labs), and imaged at 60
magnification using a Widefield Deltavision microscope.
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FECD donor corneas with confluent corneal endothelial gut-
tae on specular microscopy and the TCF4 expansion and control
donor corneas were bisected and incubated in Optisol GS cor-
neal storage media with control LNA (LC) or LNA1 (final concen-
tration 10 lM) at 37C. After treatment for 7 days, RNA FISH
analysis was performed on the dissected Descemet’s mem-
brane-endothelium monolayers from the right eye from each
donor to assess CUGexp sense foci as described above. After
treatment for 9 days, the total RNA was extracted from the dis-
sected Descemet’s membrane-endothelium monolayers using
TRIzol (ThermoScientific) per manufacturer’s instructions.
Alternative splicing of MBNL1-sensitive exons were assessed by
RT-PCR as described previously (16) using endothelial tissue
from corresponding left eyes of donors.
Statistics
Correlation between four foci parameters (percentage of total
cells with sense foci, number of sense foci per 100 cells, percent-
age of total cells with antisense foci and number of antisense
foci per 100 cells) and age, sex and CTG repeat number were
examined on the 20 FECD subjects by linear regression models.
Study approval
The study was approved by the institutional review board of the
University of Texas Southwestern Medical Center and con-
ducted in adherence with the tenets of the Declaration of
Helsinki. Written informed consent was obtained from partici-
pants prior to inclusion in the study.
Supplementary Material
Supplementary Material is available at HMG online.
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